Citigroup initiated coverage on shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) in a report released on Monday, The Fly reports. The firm issued a buy rating on the stock.

MOR has been the subject of several other research reports. Barclays reissued an equal weight rating on shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 in a research note on Wednesday, May 13th. Royal Bank of Canada cut shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 from an outperform rating to a sector perform rating in a research note on Thursday, June 25th. Zacks Investment Research cut shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 from a strong-buy rating to a hold rating in a research note on Thursday, July 23rd. Finally, HSBC raised shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 from a reduce rating to a hold rating in a research note on Tuesday, May 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a consensus rating of Hold and an average price target of $38.00.

MOR stock opened at $32.55 on Monday. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a 12 month low of $18.21 and a 12 month high of $37.96. The firm has a 50-day moving average of $32.91 and a two-hundred day moving average of $29.56.

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

See Also: Hold Rating

The Fly

Analyst Recommendations for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR)

Receive News & Ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 and related companies with MarketBeat.com's FREE daily email newsletter.